Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center

GND
109579230X
ORCID
0000-0001-9367-7130
Affiliation
Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany
Guder, Wiebke K.;
GND
124136923
Affiliation
Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany
Hardes, Jendrik;
GND
1313505803
ORCID
0009-0006-4461-9923
Affiliation
Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany
Nottrott, Markus;
GND
1233757652
Affiliation
Department of Orthopedics and Tumor Orthopedics, University Hospital Muenster, Muenster, Germany
Steffen, Anne Juliane;
GND
115298789
ORCID
0000-0002-5435-7860
Affiliation
Department of Pediatric Hematology and Oncology (III), University Hospital Essen, Essen, Germany
Dirksen, Uta;
GND
129565180
Affiliation
Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany
Streitbürger, Arne

Abstract: Background Local treatment in pelvic Ewing sarcoma (ES) consists of operation, radiation therapy, or a combination of both. Reported outcomes vary depending on the treatment modality performed. It is the objective of this study to analyze surgical outcome and complications as well as oncological outcome and complications of chemo- and radiation therapy in this patient cohort and evaluate prognostic factors.

Methods: Retrospective review of 104 patients who underwent tumor resection for pelvic ES from 1988 to 2014.

Results: All patients underwent pelvic resection and radiation therapy was administered in 77.9%. Margins were clear in 94.2%. The response to chemotherapy was good in 78.8%. Local recurrence occurred in 7.7%. The presence of distant metastases at the time of operation was the most important negative predictor for overall survival ( p = 0.003). The cumulative 5- and 10-year survival rates were 82.7% and 80.1% for non-metastasized and 61.4% and 41.6% for metastasized pelvic ES at operation. In the presence of a single-distant metastatic site at operation compared to multiple metastatic sites, the cumulative survival rates were 64.3% versus 50% at five and 50.7% versus 16.7% at 10 years.

Conclusions: A combined treatment approach of tumor resection and radiation therapy leads to a local control and overall survival rates comparable with those of extremity locations in this study’s patient cohort with localized pelvic ES. Therefore, surgical tumor resection (combined with (neo-)adjuvant radiation therapy) in non-metastatic pelvic ES seems feasible. In metastatic patients, however, the significance of tumor resection as a part of local treatment remains less certain and improved outcomes of combined local treatment approaches need to be weighed against these patients’ prognosis and quality of life.

Cite

Citation style:
Could not load citation form.

Rights

License Holder:

© The Author(s) 2020

Use and reproduction:
This work may be used under a
CC BY 4.0 LogoCreative Commons Attribution 4.0 License (CC BY 4.0)
.